Cancer Survivor's Pac-Man Battle Against Lymphoma

A New Jersey woman diagnosed with diffuse large B-cell lymphoma experienced a recurrence of the aggressive blood cancer in her brain, leading to a dismal prognosis. Initial chemotherapy provided only temporary relief, prompting her care team to consider a personalized immunotherapy called CAR-T. This innovative treatment involves genetically engineering a patient's own T-cells to target and destroy cancer cells.

In January 2025, she underwent the CAR-T infusion, visualizing the process like a video game where her cells would "Pac-Man" the cancer. The treatment proved remarkably successful with no side effects, leading to her discharge from the hospital within two weeks.

Now, one year later as of March 2026, she is in complete remission with no evidence of disease. She will continue to have scans every four to six months to monitor for any recurrence. This experience has profoundly shifted her perspective on life, prioritizing family and meaningful connections.

Diffuse large B-cell lymphoma is a fast-growing blood cancer affecting approximately 25,000 people in the U.S. annually. CAR-T therapy, while relatively new, is showing promise not only for lymphoma but also for leukemia, myeloma, and even autoimmune diseases, with potential applications continuously expanding.